The strain and food matrix were specified
The randomized, double-blind trial enrolled 210 Japanese adults with relatively large visceral fat areas. Participants consumed fermented milk containing one of two concentrations of L. gasseri SBT2055 or fermented milk without that strain for 12 weeks. [1]
The active groups had reductions from baseline in CT-measured visceral fat area, reported at about 8%. The control group did not show a significant baseline reduction. These percentages concern visceral fat area, not an 8% reduction in total body weight. [1]
The result did not demonstrate a permanent change
The reported effects weakened during four weeks after participants stopped taking the fermented milk. The abstract does not establish durability beyond that period or equivalence of an unrelated capsule. [1]
A strain-specific food trial also does not identify an effect for all people or all gasseri strains. Funding and conflicts were not fully assessed from the abstract; this page reports the narrow study finding rather than ranking retail weight-loss products. [1]
Keep the denominator attached
Imagine a scan-derived fat area falls by 8%. Reporting that as 8% body-weight loss would change the outcome and exaggerate what the measurement says.
| Detail | Interpretation |
|---|---|
| SBT2055 | Named strain |
| Fermented milk | Tested delivery |
| Visceral fat area | Not total body weight |
Sources for this article
- Effect of Lactobacillus gasseri SBT2055 in fermented milk on abdominal adiposity in adults in a randomised controlled trial - PubMed
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.